CN111920048A - 一种含有玫瑰发酵液的胶囊及其制备方法 - Google Patents
一种含有玫瑰发酵液的胶囊及其制备方法 Download PDFInfo
- Publication number
- CN111920048A CN111920048A CN202010836762.0A CN202010836762A CN111920048A CN 111920048 A CN111920048 A CN 111920048A CN 202010836762 A CN202010836762 A CN 202010836762A CN 111920048 A CN111920048 A CN 111920048A
- Authority
- CN
- China
- Prior art keywords
- rose
- rose fermentation
- fermentation liquor
- fermentation
- cicc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000855 fermentation Methods 0.000 title claims abstract description 107
- 230000004151 fermentation Effects 0.000 title claims abstract description 107
- 241000220317 Rosa Species 0.000 title claims abstract description 84
- 239000002775 capsule Substances 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims description 30
- 229920001202 Inulin Polymers 0.000 claims abstract description 17
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 17
- 229940029339 inulin Drugs 0.000 claims abstract description 17
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 14
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 14
- 150000004676 glycans Chemical class 0.000 claims abstract description 14
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 14
- 239000005017 polysaccharide Substances 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 230000001580 bacterial effect Effects 0.000 claims description 43
- 239000007788 liquid Substances 0.000 claims description 43
- 230000001954 sterilising effect Effects 0.000 claims description 34
- 239000001963 growth medium Substances 0.000 claims description 31
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 26
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 26
- 230000004913 activation Effects 0.000 claims description 22
- 239000002609 medium Substances 0.000 claims description 20
- 239000007787 solid Substances 0.000 claims description 20
- 238000001914 filtration Methods 0.000 claims description 19
- 238000004659 sterilization and disinfection Methods 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 244000063299 Bacillus subtilis Species 0.000 claims description 17
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 17
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims description 17
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims description 17
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 16
- 238000004108 freeze drying Methods 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 229920002774 Maltodextrin Polymers 0.000 claims description 11
- 239000011259 mixed solution Substances 0.000 claims description 11
- 241000628997 Flos Species 0.000 claims description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 10
- 239000005913 Maltodextrin Substances 0.000 claims description 10
- 229940035034 maltodextrin Drugs 0.000 claims description 10
- 239000000758 substrate Substances 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 7
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 6
- 229920001817 Agar Polymers 0.000 claims description 5
- 239000001888 Peptone Substances 0.000 claims description 5
- 108010080698 Peptones Proteins 0.000 claims description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 5
- 239000008272 agar Substances 0.000 claims description 5
- 235000015278 beef Nutrition 0.000 claims description 5
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 5
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 5
- 229940099596 manganese sulfate Drugs 0.000 claims description 5
- 239000011702 manganese sulphate Substances 0.000 claims description 5
- 235000007079 manganese sulphate Nutrition 0.000 claims description 5
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 5
- 235000019319 peptone Nutrition 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 239000001632 sodium acetate Substances 0.000 claims description 5
- 235000017281 sodium acetate Nutrition 0.000 claims description 5
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 claims description 5
- 239000001393 triammonium citrate Substances 0.000 claims description 5
- 235000011046 triammonium citrate Nutrition 0.000 claims description 5
- 241001052560 Thallis Species 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000006872 mrs medium Substances 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 abstract description 19
- 235000013406 prebiotics Nutrition 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 14
- 239000013543 active substance Substances 0.000 abstract description 10
- 229930003944 flavone Natural products 0.000 abstract description 10
- 235000011949 flavones Nutrition 0.000 abstract description 10
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 abstract description 9
- 150000002212 flavone derivatives Chemical class 0.000 abstract description 9
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 abstract description 9
- 150000001413 amino acids Chemical class 0.000 abstract description 7
- 241000588724 Escherichia coli Species 0.000 abstract description 6
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 6
- 241000186012 Bifidobacterium breve Species 0.000 abstract description 5
- 241000186869 Lactobacillus salivarius Species 0.000 abstract description 5
- 241000109329 Rosa xanthina Species 0.000 abstract description 4
- 235000004789 Rosa xanthina Nutrition 0.000 abstract description 4
- 244000052616 bacterial pathogen Species 0.000 abstract description 4
- 230000001105 regulatory effect Effects 0.000 abstract description 4
- 230000002087 whitening effect Effects 0.000 abstract description 4
- 206010067484 Adverse reaction Diseases 0.000 abstract description 3
- 230000006838 adverse reaction Effects 0.000 abstract description 3
- 238000013329 compounding Methods 0.000 abstract description 3
- 230000003020 moisturizing effect Effects 0.000 abstract description 3
- 239000008132 rose water Substances 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- 230000008092 positive effect Effects 0.000 abstract description 2
- 239000006041 probiotic Substances 0.000 abstract description 2
- 235000018291 probiotics Nutrition 0.000 abstract description 2
- 238000001035 drying Methods 0.000 description 19
- 241000894006 Bacteria Species 0.000 description 18
- 239000000047 product Substances 0.000 description 15
- 238000009630 liquid culture Methods 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 13
- 230000009286 beneficial effect Effects 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 8
- 241000186000 Bifidobacterium Species 0.000 description 6
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 4
- 235000017491 Bambusa tulda Nutrition 0.000 description 4
- 241001330002 Bambuseae Species 0.000 description 4
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000011425 bamboo Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000007598 dipping method Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000005374 membrane filtration Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- -1 sucrose triose Chemical class 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000001471 micro-filtration Methods 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 1
- 241000741973 Bifidobacterium breve DSM 20213 = JCM 1192 Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 241001104460 Lactobacillus salivarius DSM 20555 = ATCC 11741 Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000021049 nutrient content Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000008621 organismal health Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
- C12N1/18—Baker's yeast; Brewer's yeast
- C12N1/185—Saccharomyces isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/85—Saccharomyces
- C12R2001/865—Saccharomyces cerevisiae
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明提供了一种含有玫瑰发酵液的胶囊,其中玫瑰发酵液富含多糖、黄酮和氨基酸,具有调节肠道微生态的作用。且玫瑰发酵液可以促进益生菌(如短双歧杆菌、唾液乳杆菌)生长,而对大肠杆菌、金黄色葡萄球菌等致病菌有明显的抑制作用。因此,玫瑰对肠道菌群具益生元作用。通过发酵得到的玫瑰发酵液比玫瑰水提物含有更多的黄酮、多糖、氨基酸等活性物,具有抗炎、美白、保湿等养肤功效。本发明还向该产品中加入菊粉和低聚果糖对玫瑰发酵液进行复配,这一配料方式能够统筹各原料优点,放大该产品对肠道菌群以及健康的正相作用,同时可以减轻不良反应。
Description
技术领域
本发明涉及轻化工业技术领域,具体涉及一种含有玫瑰发酵液的胶囊,以及该胶囊的制备方法。
背景技术
上世纪60年代以来,随着对肠道微生物学的深入研究,表明肠道菌群对机体健康的确有莫大影响,与人体免疫、衰老、疾病发生等都有着密切关系。按对人体健康的影响可以分为有益、有害、无害三群,在正常情况下这三群细菌处于相对平衡的状态,若人体有益菌如双歧杆菌、乳酸菌等处于优势,则对净化肠道、改善营养,维持人体健康起到重要作用。
益生元是指能选择性地刺激肠道内有益菌生长和繁殖,增强有益菌新陈代谢,使人体向健康的方向发展。近十年来,国内外学者对益生元开展了大量研究,发现益生元具有改善肠道内生态环境,增强有益菌群数量,促进矿物质吸收,调节脂肪代谢功能,增强自身免疫系统,降低癌症及心血管等突发病症的作用。
随着科学技术的发展,人们的生活水平提高,人们对健康的追求越来越强烈,人们意识到环境污染,以及抗生素滥用等使肠道菌群平衡被破坏,而益生元可以调节肠道菌群,使其恢复平衡,普通消费者对于益生元的认知也越来越深,关注度和认可度也在提高,这使得近年来对益生元的开发、生产需求逐渐提高并且要求多样化。并且益生元的应用人群覆盖很广,从婴儿、儿童、青年到老年人都有涉及,所以潜在消费者非常多。然而如今食品上益生元产品数量较少,还有很大的开发需求,并且市面上的产品成分单一,添加量不高,效果不明显,而且有些消费者出现食用后腹泻等不良反应。因此需要针对上述问题对益生元产品进行改进。
鉴于此,特提出本发明。
发明内容
本发明的第一目的在于提供一种含有玫瑰发酵液的胶囊。
本发明的第二目的在于提供上述胶囊的制备方法。
为实现上述目的,本发明的技术方案如下:
本发明涉及一种含有玫瑰发酵液的胶囊,包括以下重量份的原料:玫瑰发酵液70~85份、菊粉3~10份、低聚果糖3~7份,麦芽糊精8~15份。
本发明还涉及所述胶囊的制备方法,包括以下步骤:
(1)配料:将所述玫瑰发酵液、菊粉、低聚果糖和麦芽糊精投入配料罐中,然后加入纯水;
(2)搅拌溶解:控制所述配料罐内温度为45~55℃,搅拌至各组分混合均匀;
(3)灭菌和过滤:将所述配料罐升温至75~90℃,持续搅拌保持温度灭菌30~40min,过滤后得到浓缩液;
优选地,采用5μm滤芯进行杂质过滤。
(4)冷冻干燥:将所述浓缩液冷冻干燥后,进行胶囊填充,得到所述含有玫瑰发酵液的胶囊。
优选地,所述冷冻干燥包括预冻和冻干,所述预冻是-60℃冷冻6h,然后进行冻干,所述冻干过程包括:-60℃干燥10h,-40℃干燥5h,-20℃干燥5h,0℃干燥5h,20℃干燥10h,40℃干燥5h。
本发明还涉及所述玫瑰发酵液的制备方法,包括以下步骤:
1)玫瑰发酵基质制备:将干玫瑰花蕾粉碎后过筛,并加水配成混合液,灭菌后得到玫瑰发酵基质。
优选地,所述筛网的目数为100~200目。
优选地,所述混合液的质量浓度为10%~15%。
优选地,所述灭菌为将所述混合液在121℃下灭菌15min,或对其在600MPa,25℃下进行超高压灭菌。
2)菌种活化:采用平板划线法将菌种分别接种到固体活化培养基表面,于37℃恒温倒置培养15~20h,得到活化菌株;
优选地,所述菌种选自双歧杆菌、芽孢杆菌、乳杆菌、酿酒酵母中的至少一种。
优选地,所述菌种选自青春双歧杆菌CICC 6175、纳豆芽孢杆菌CICC 10262、保加利亚乳杆菌CICC 20271、酿酒酵母菌CICC 1252中的至少一种。
优选地,所述活化培养基为MRS培养基,包括牛肉膏5g/L,蛋白胨10g/L,葡萄糖20g/L,酵母粉4g/L,乙酸钠5g/L,硫酸镁0.2g/L,柠檬酸三铵2g/L,磷酸氢二钾2g/L,硫酸锰0.05g/L,吐温-80 1g/L,琼脂20g/L,pH值6.2±0.2。
优选地,所述活化培养基还包括海藻多糖,所述海藻多糖的加入量为3g/L。
3)混合发酵:将所述活化菌株扩大培养后进行混合得到混合菌液,将所述混合菌液以1.5%~2.5%的质量百分含量加入玫瑰发酵基质中,于40~45℃摇床发酵培养45~50h,得到初始发酵液;
优选地,所述摇床转速为100~150rpm。
优选地,所述菌种为纳豆芽孢杆菌CICC 10262、保加利亚乳杆菌CICC 20271和酿酒酵母菌CICC 1252的混合菌种,扩大培养后的所述纳豆芽孢杆菌CICC 10262、保加利亚乳杆菌CICC 20271和酿酒酵母菌CICC 1252的种子液质量比例为1:(2~5):(2~5)。
4)发酵后处理:对所述初始发酵液依次进行灭菌、菌体破碎和过滤后,得到所述玫瑰发酵液。
优选地,所述灭菌为将所述初始发酵液在121℃下灭菌15min,或对其在600MPa,25℃下进行超高压灭菌。
优选地,所述过滤选自离心分离、超滤膜过滤、微滤膜过滤、反渗透过滤中的一种,或者在灭菌后破碎菌体无需进行过滤。
优选地,采用高压匀浆机破碎菌体,压力设定为100MPa,匀浆3~5次,出口温度为25℃。
本发明的有益效果:
本发明提供了一种含有玫瑰发酵液的胶囊,其中玫瑰发酵液富含多糖、黄酮和氨基酸,具有调节肠道微生态的作用。且玫瑰发酵液可以促进益生菌(如短双歧杆菌、唾液乳杆菌)生长,而对大肠杆菌、金黄色葡萄球菌等致病菌有明显的抑制作用。因此,玫瑰对肠道菌群具益生元作用。通过发酵得到的玫瑰发酵液比玫瑰水提物含有更多的黄酮、多糖、氨基酸等活性物,具有抗炎、美白、保湿等养肤功效。
本发明还向该产品中加入菊粉和低聚果糖对玫瑰发酵液进行复配,这一配料方式能够统筹各原料优点,放大该产品对肠道菌群以及健康的正相作用,同时可以减轻不良反应。
此外本发明将该产品制成胶囊,在隔离空气的同时可以防潮、避光,提高产品稳定性。而且与片剂和丸剂相比,胶囊服用后释药更迅速,药物生物利用度高;与颗粒剂相比,可减少辅料的用量,节约成本,且具有服用和携带方便的优点。
附图说明
图1为本发明玫瑰发酵液的制备流程图。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚,下面将对本发明的技术方案进行详细的描述。显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动的前提下所得到的所有其它实施方式,都属于本发明所保护的范围。
本发明实施例涉及一种含有玫瑰发酵液的胶囊,包括以下重量份的原料:玫瑰发酵液70~85份、菊粉3~10份、低聚果糖3~7份,麦芽糊精8~15份。
其中,玫瑰花含有多种营养成分。文献报道玫瑰花能够抑制肠道有害菌生长,促进有益菌的生长,因此玫瑰花具有作为益生元的潜力。由于玫瑰花的许多活性成分存在于细胞内,如采用发酵菌对玫瑰花进行发酵,有利于玫瑰细胞的破裂,从而释放其有效成分。并且对比传统玫瑰水提取方法,玫瑰发酵也可以得到更多的活性物质,例如多糖、黄酮;与传统有机试剂提取相比,发酵提取更加环保和安全。此外,发酵还能使玫瑰花内的活性物质大分子降解为小分子,利于功效成分的吸收。因此本发明采用玫瑰发酵液来制备肠道益生元胶囊。
菊粉是植物中储备性多糖,主要来源于植物。菊粉分子约由31个β-D-呋喃果糖和1~2个吡喃菊糖残基聚合而成,果糖残基之间能通过β-2,1-键连接。是由D-果糖经β(1→2)糖苷键链接而成的线性直链多糖。摄入菊粉可有效降低血清总胆固醇(TC)和低密度脂蛋白胆固醇(LDL-C),提高高密度脂蛋白/低密度脂蛋白比率,改善血脂状况,还能够降低血糖和促进矿物质的吸收。菊粉还是一种天然的水溶性膳食纤维,几乎不能被胃酸水解和消化,只有在结肠被有益微生物利用,从而改善肠道环境,增强胃肠道蠕动,防止便秘。
低聚果糖又称寡果糖或蔗糖三糖族低聚糖。包括蔗糖分子以β-(1→2)糖苷键与1-3个果糖分子结合成的蔗果三糖,蔗果四糖和蔗果五糖,属于果糖和葡萄糖构成的直链杂低聚糖。低聚果糖通过选择性促进乳酸杆菌、双歧杆菌和链球菌等有益菌在消化道中的定植,抑制有害细菌生长,改善肠道菌群,间接达到对动物体的营养及促生长效应。促进B族维生素及叶酸的形成,能维护神经系统的正常功能,促进消化及新陈代谢,减少肝脏毒素,增强人体免疫力。
麦芽糊精也称水溶性糊精或酶法糊精。它是以各类淀粉作原料,经酶法工艺低程度控制水解转化,提纯,干燥而成。在胶囊中主要作为粘合剂和填充剂。
如今市面上的益生元产品很少,并且成分单一,效果不明显。本胶囊采取复配的方法,添加了菊粉、低聚果糖和玫瑰发酵液。可以更加全面地调节肠道菌群,维持肠道和身体健康。
本发明实施例还涉及该胶囊的制备方法,包括以下步骤:
(1)配料:将玫瑰发酵液、菊粉、低聚果糖和麦芽糊精按重量比投入配料罐中,然后加入纯水;
在本发明的一个实施例中,玫瑰发酵液、菊粉、低聚果糖和麦芽糊精的质量和与纯水的体积比为(84~117kg):(8~12L)。
(2)搅拌溶解:控制配料罐内温度为45~55℃,搅拌至各组分混合均匀;
(3)灭菌和过滤:将配料罐升温至75~90℃,持续搅拌保持温度灭菌30~40min,过滤后得到浓缩液,优选采用5μm滤芯进行杂质过滤。
(4)冷冻干燥:将浓缩液冷冻干燥后,进行胶囊填充,得到含有玫瑰发酵液的胶囊。
在本发明的一个实施例中,冷冻干燥包括预冻和冻干,所述预冻是-60℃冷冻6h,然后进行冻干,所述冻干过程包括:-60℃干燥10h,-40℃干燥5h,-20℃干燥5h,0℃干燥5h,20℃干燥10h,40℃干燥5h。
本发明还涉及玫瑰发酵液的制备方法,其制备流程图如图1所示,包括以下步骤:
1)玫瑰发酵基质制备:将干玫瑰花蕾粉碎后过筛,并加水配成混合液,灭菌后得到玫瑰发酵基质。
在本发明的一个实施例中,筛网的目数为100~200目。混合液的质量浓度为10%~15%。
在本发明的一个实施例中,灭菌为将混合液在121℃下灭菌15min,或对混合液进行软包装后,用水作为介质,在600MPa,25℃下进行超高压灭菌。超高压灭菌的温度较低,可保护多酚、黄酮类物质,但超高压灭菌成本高,可根据实际情况选择灭菌方式。
2)菌种活化:采用平板划线法将菌种分别接种到固体活化培养基表面,于37℃恒温倒置培养15~20h,得到活化菌株。菌种活化的目的是使保藏菌种的活性得以恢复,同时恢复其优良的生产性能。
在本发明的一个实施例中,菌种选自双歧杆菌、芽孢杆菌、乳杆菌、酿酒酵母中的至少一种。
进一步地,菌种选自青春双歧杆菌CICC 6175、纳豆芽孢杆菌CICC10262、保加利亚乳杆菌CICC 20271、酿酒酵母菌CICC 1252中的至少一种。
优选地,菌种为纳豆芽孢杆菌CICC 10262、保加利亚乳杆菌CICC 20271和酿酒酵母菌CICC 1252的混合菌种。
在本发明的一个实施例中,用于菌种活化的活化培养基为MRS培养基,包括牛肉膏5g/L,蛋白胨10g/L,葡萄糖20g/L,酵母粉4g/L,乙酸钠5g/L,硫酸镁0.2g/L,柠檬酸三铵2g/L,磷酸氢二钾2g/L,硫酸锰0.05g/L,吐温-80 1g/L,琼脂20g/L,pH值6.2±0.2。
进一步地,活化培养基还包括海藻多糖,所述海藻多糖可作为碳源加入,有利于菌株活化,对于菌落直径、形态、菌体体积以及长出的菌落时间都有正向效果。优选海藻多糖的加入量为3g/L。
进一步地,菌种活化方式为:用灭菌竹签蘸取少量的菌种,按照平板划线法在固体活化培养基上划线,于37℃的恒温培养箱中倒置培养15~20h,得到活化菌株。由于双歧杆菌和乳杆菌需要无氧条件活化,芽孢杆菌和酿酒酵母需要有氧活化,可以将双歧杆菌、乳杆菌、芽孢杆菌和酿酒酵母分别接种于不同的固体活化培养基,然后在适宜的条件下培养,待混合发酵步骤将上述活化菌株加入玫瑰发酵基质中即可。
3)混合发酵:将活化菌株扩大培养后,按照比例混合得到混合菌液,将所述混合菌液以1.5%~2.5%的质量百分含量加入玫瑰发酵基质中,于40~45℃摇床发酵培养45~50h,得到初始发酵液。
在本发明的一个实施例中,采用MRS液体培养基进行扩大培养,包括牛肉膏5g/L,蛋白胨10g/L,葡萄糖20g/L,酵母粉4g/L,乙酸钠5g/L,硫酸镁0.2g/L,柠檬酸三铵2g/L,磷酸氢二钾2g/L,硫酸锰0.05g/L,吐温-80 1g/L,pH值6.2±0.2。不同菌种的扩大培养方法如下:
[1]对于酿酒酵母菌CICC 1252,固体培养基活化后,用接种针或接种环从固体培养基菌落中挑取菌落,放入装有液体培养基的三角瓶中,轻微摆动接种针,使菌体分散于液体培养基内,37℃,120rpm培养,直到菌种数量达到1*10^9cfu/mL时结束,得到酿酒酵母种子液。
[2]对于纳豆芽孢杆菌CICC 10262,固体培养基活化后,用接种针或接种环从固体培养基菌落中挑取菌落,放入装有液体培养基的三角瓶中,轻微摆动接种针,使菌体分散于液体培养基内,37℃,120rpm培养,直到菌种数量达到1*10^9cfu/mL时结束,得到纳豆芽孢杆菌种子液。
[3]对于青春双歧杆菌CICC 6175,由于在无氧条件进行活化,需要对其进行耐氧训练。具体为固体培养基活化后,用接种针或接种环从固体培养基菌落中挑取菌落,放入装有液体培养基的三角瓶中,静置培养24h;吸取上步骤菌液再接种到装有液体培养基的三角瓶中,接种量为5%,37℃,20rpm培养12h;吸取上步骤菌液再接种到装有液体培养基的三角瓶中,接种量为10%,37℃,60rpm培养12h;吸取上步骤菌液再接种到装有液体培养基的三角瓶中,接种量为15%,37℃,120rpm培养,直到菌种数量达到1*10^9cfu/mL时结束,得到青春双歧杆菌种子液;
[4]对于保加利亚乳杆菌CICC 20271,由于在无氧条件进行活化,需要对其进行耐氧训练。具体为固体培养基活化后,用接种针或接种环从固体培养基菌落中挑取菌落,放入装有液体培养基的三角瓶中,静置培养24h;吸取上步骤菌液再接种到装有液体培养基的三角瓶中,接种量为5%,37℃,20rpm培养12h;吸取上步骤菌液再接种到装有液体培养基的三角瓶中,接种量为10%,37℃,60rpm培养12h;吸取上步骤菌液再接种到装有液体培养基的三角瓶中,接种量为15%,37℃,120rpm培养,直到菌种数量达到1*10^9cfu/mL时结束,得到保加利亚乳杆菌种子液。
扩大培养后的纳豆芽孢杆菌CICC 10262、保加利亚乳杆菌CICC 20271和酿酒酵母菌CICC 1252种子液的质量比例为1:(2~5):(2~5)。申请人研究发现,当发酵菌种满足上述配比时,得到的玫瑰发酵液中含有较多的黄酮和糖类物质。
在步骤3)中,采用摇床培养可以使菌种与发酵底物充分接触,优选的摇床转速为100~150rpm。
4)发酵后处理:对初始发酵液依次进行灭菌、菌体破碎和过滤后,得到玫瑰发酵液。
与步骤1)类似,灭菌为将初始发酵液在121℃下灭菌15min,或对其在600MPa,25℃下进行超高压灭菌。
过滤选自离心分离、超滤膜过滤、微滤膜过滤、反渗透过滤中的一种,或者在灭菌后破碎菌体无需进行过滤,目的是除去悬浮物,防止沉降。
采用高压匀浆机破碎菌体,目的是破碎发酵菌及部分玫瑰细胞,使胞内物质溶出,玫瑰发酵液的成分更丰富。高压匀浆压力设定为100MPa,匀浆3~5次,出口温度为25℃。也可采用超声破碎菌体。
制备例玫瑰发酵液的制备
制备例1
1)玫瑰发酵基质制备:将干玫瑰花蕾粉碎后过100目筛,并加水配成质量浓度为10%的混合液,121℃下灭菌15min,得到玫瑰发酵基质。
2)菌种活化:用灭菌竹签蘸取纳豆芽孢杆菌CICC 10262,按照平板划线法在固体活化培养基上划线,于37℃的恒温培养箱中倒置有氧培养15~20h,得到活化纳豆芽孢杆菌CICC 10262菌株。
用灭菌竹签蘸取保加利亚乳杆菌CICC 20271,按照平板划线法在固体活化培养基上划线,于37℃的恒温培养箱中倒置无氧培养15~20h,得到活化保加利亚乳杆菌CICC20271菌株。
用灭菌竹签蘸取酿酒酵母菌CICC 1252,按照平板划线法在固体活化培养基上划线,于37℃的恒温培养箱中倒置有氧培养15~20h,得到活化酿酒酵母菌CICC 1252菌株。
活化培养基为MRS培养基,包括牛肉膏5g/L,蛋白胨10g/L,葡萄糖20g/L,酵母粉4g/L,乙酸钠5g/L,硫酸镁0.2g/L,柠檬酸三铵2g/L,磷酸氢二钾2g/L,硫酸锰0.05g/L,吐温-80 1g/L,琼脂20g/L,pH值6.2±0.2。
3)混合发酵:将活化菌株分别扩大培养,以纳豆芽孢杆菌CICC 10262、保加利亚乳杆菌CICC 20271和酿酒酵母菌CICC 1252的种子液质量比例为1:3:3混合,把混合菌液按照2%的质量百分含量加入玫瑰发酵基质中,于40℃,120rpm摇床发酵培养48h,得到初始发酵液。
4)发酵后处理:对初始发酵液在121℃下灭菌15min后,使用High PressureHomogenizer高压匀浆机进行菌体破碎,压力设定为100MPa,匀浆3次,出口温度为25℃,然后离心分离取上清液,得到玫瑰发酵液。
制备例2~8改变某一项实验参数,其它操作步骤和测试过程同制备例1,具体设置方式见表1。制备例中的青春双歧杆菌CICC 6175、纳豆芽孢杆菌CICC 10262、保加利亚乳杆菌CICC 20271、酿酒酵母菌CICC 1252均购自中国工业微生物菌种保藏管理中心。
对比例1中的玫瑰提取液的提取方法为:将干玫瑰花蕾粉碎后过100目筛,并加水配成质量浓度为10%的混合液,121℃下灭菌15min,然后在40℃下保温48h,再在121℃下灭菌15min,离心分离取上清液,即得到清水提取液。
对比例2中的玫瑰发酵液的制备方法为:将步骤2)中的活化培养基替换为沙氏葡萄糖液体培养基。
表1
营养成分检测
对于制备例1至12制备得到的玫瑰发酵液,以及对比例1和2制备得到的玫瑰提取液,采用分光光度法测定总黄酮含量;参照GB/T 5009.7-2008测定总糖含量;参照GB/T5009.124-2003测定氨基酸含量。测试结果见表2和表3。
表2玫瑰发酵液各成分含量
表3玫瑰发酵液氨基酸含量
上述实验结果表明,比较制备例1和对比例1可知,与传统玫瑰水提物相比,本发明的玫瑰发酵液含有更多的活性物质,例如多糖、黄酮和氨基酸。
比较制备例1~6以及制备例11和12可知,采用纳豆芽孢杆菌CICC10262、保加利亚乳杆菌CICC 20271和酿酒酵母菌CICC 1252作为发酵菌种,且三者质量比例满足1:(2~5):(2~5)时,玫瑰发酵液中的活性物质含量最高。
比较制备例1和7~9可知,如果在此基础上向活化培养基和扩大培养基中均加入海藻多糖,能够进一步提升活性物质含量。但将海藻多糖替换为葡萄糖或米粉则不具有相应效果,原因可能是海藻多糖刺激菌种表达了某些基因,使其分解、合成活性物质的能力提升,并且使菌生长状态更加旺盛,活力更强。
比较制备例1与10可知,混合发酵过程中,摇床上培养比静置培养有更多活性物质,原因可能是摇床使发酵菌与玫瑰充分接触,使活性成分更易产生和流出。
比较制备例1与11和12可知,黄酮含量有所升高,原因可能是超高压灭菌可以保护黄酮,减少其被氧化。
比较制备例1和对比例2可知,采用固体活化培养基与液体活化培养基相比,能获得更多的活性物质。并且与液体培养基相比,固体培养基单位体积的质量更轻,而且对生产过程中所需设备要求较低。大量培育液体菌种需要在大型液体发酵罐中进行,对场地、能源(蒸汽)的需求较高;而使用固体培养基培育菌种,仅需灭菌设备即可,在条件较低的情况下即可生产。
抑菌实验
(1)将金黄色葡萄球菌ATCC6538接种于营养肉汤培养基,短双歧杆菌ATCC15700和唾液乳杆菌ATCC11741培养于TPY培养基,大肠杆菌ATCC25312培养于LB培养基。
(2)每种培养液各取10mL,各2份,分别加入0.1mL制备例1的玫瑰发酵液和0.1mL去离子水作为空白对照。
(3)将金黄色葡萄球菌、大肠杆菌置于37℃下进行24h需氧培养,将短双歧杆菌和唾液乳杆菌置于37℃下进行48h厌氧培养。
(4)用稀释平板法测定培养前后培养液中各种菌的数目,测试结果如表4所示。
表4
以3.1*10^6为例,含义为3.1×106。
表4数据可以看出,加入玫瑰发酵液培养,金黄色葡萄球菌、大肠杆菌这类有害菌数量比不加入玫瑰发酵液的空白组降低很多,但短双歧杆菌、唾液乳杆菌这类有益菌比不加入玫瑰发酵液的空白组增加了。说明本发明的玫瑰提取液可以作用于肠道微生物,特别是能够选择性抑制大肠杆菌和金黄色葡萄球菌等有害菌的生长,同时促进短双歧杆菌、唾液乳杆菌这类有益菌的生长,从而调节肠道菌群,使其达到健康平衡的状态。将其用于胶囊中,能够调节肠道微生态,达到促进人体健康的效果。
实施例胶囊的制备
实施例1
(1)配料:将玫瑰发酵液80份、菊粉5份、低聚果糖5份和麦芽糊精10份按重量比投入配料罐中,然后加入纯水;
其中,菊粉购自西安浩天生物工程有限公司,低聚果糖购自广州鸿易食品添加剂有限公司,麦芽糊精购自西安大丰收生物科技有限公司。上述玫瑰发酵液、菊粉、低聚果糖和麦芽糊精的质量和与纯水的体积比为(84~117kg):(8~12L)。
(2)搅拌溶解:控制配料罐内温度为50℃,搅拌至各组分混合均匀;
(3)灭菌和过滤:将配料罐升温至80℃,持续搅拌保持温度灭菌30min,采用5μm滤芯过滤后得到浓缩液;
(4)冷冻干燥:将浓缩液在-60℃预冻6h后,然后进行冻干,冻干过程包括:-60℃干燥10h,-40℃干燥5h,-20℃干燥5h,0℃干燥5h,20℃干燥10h,40℃干燥5h;
(5)将冻干物进行胶囊填充,得到含有玫瑰发酵液的胶囊。
实施例2~4和对比例3~4改变某一项实验参数,其它操作步骤和测试过程同实施例1,具体设置方式见表5。
表5
皮肤含水量测试
选取实验室里7名志愿者,年龄范围18~40岁,其中6名志愿者分别服用了制备例1~4和对比例3~4制备的胶囊,服用量为每天1颗。第7名志愿者不服用胶囊。测试期间只能使用基础类护肤品,不能使用任何功效类护肤品,同时注意防晒。
选取脸颊两侧作为测试部位,在实验第0,14,30天采用皮肤水分测试仪水分测试探头Corneometer CM825测试其头皮角质层含水量,测试三次取平均值,结果如表6所示;在实验第0,14,30天使用皮肤颜色测试探头Colorimeter CL400测试皮肤亮度变化;测试三次取平均值,结果如表7所示。
表6皮肤角质层含水量对比
表7皮肤亮度对比
L值 | 实施例1 | 实施例2 | 实施例3 | 实施例4 | 对比例3 | 对比例4 | 空白 |
0d | 56 | 52 | 57 | 59 | 54 | 58 | 56 |
14d | 56 | 53 | 58 | 59 | 54 | 58 | 56 |
28d | 57 | 54 | 60 | 60 | 54 | 59 | 56 |
结果如表6和7所示,可以看出与使用前以及空白组相比,本发明实施例1~4使用28天后,在角质层含水量以及皮肤亮度方面均有一定变化。具体地,皮肤亮度L值越大,颜色越偏向白色,L值越小则越偏向黑色。实施例1~4的L值总体趋势是增大的,能够在一定程度上反映产品美白的效果。同时角质层含水量越高,说明产品提高皮肤保湿能力越好。
将实施例2与对比例3,对比例4比较可以发现,在其他原料不变的情况下添加了玫瑰发酵液能对受试者的皮肤水润度和白度带来正向影响,如果把玫瑰发酵液换成玫瑰提取液,其水润度和白度变化都没有玫瑰发酵液那么明显。说明玫瑰发酵液能够对皮肤的水润与美白有很好的作用。
以上所述,仅为本发明的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,可轻易想到变化或替换,都应涵盖在本发明的保护范围之内。因此,本发明的保护范围应以所述权利要求的保护范围为准。
Claims (10)
1.一种含有玫瑰发酵液的胶囊,其特征在于,包括以下重量份的原料:玫瑰发酵液70~85份、菊粉3~10份、低聚果糖3~7份,麦芽糊精8~15份。
2.根据权利要求1所述的含有玫瑰发酵液的胶囊的制备方法,其特征在于,包括以下步骤:
(1)配料:将所述玫瑰发酵液、菊粉、低聚果糖和麦芽糊精投入配料罐中,然后加入纯水;
(2)搅拌溶解:控制所述配料罐内温度为45~55℃,搅拌至各组分混合均匀;
(3)灭菌和过滤:将所述配料罐升温至75~90℃,持续搅拌保持温度灭菌30~40min,过滤后得到浓缩液;
(4)冷冻干燥:将所述浓缩液冷冻干燥后,进行胶囊填充,得到所述含有玫瑰发酵液的胶囊。
3.根据权利要求1所述的含有玫瑰发酵液的胶囊,其特征在于,所述玫瑰发酵液的制备方法包括以下步骤:
1)玫瑰发酵基质制备:将干玫瑰花蕾粉碎后过筛,并加水配成混合液,灭菌后得到玫瑰发酵基质;
2)菌种活化:采用平板划线法将菌种分别接种到固体活化培养基表面,于37℃恒温倒置培养15~20h,得到活化菌株;
3)混合发酵:将所述活化菌株扩大培养后进行混合得到混合菌液,将所述混合菌液以1.5%~2.5%的质量百分含量加入玫瑰发酵基质中,于40~45℃摇床发酵培养45~50h,得到初始发酵液;
4)发酵后处理:对所述初始发酵液依次进行灭菌、菌体破碎和过滤后,得到所述玫瑰发酵液。
4.根据权利要求3所述的含有玫瑰发酵液的胶囊,其特征在于,步骤1)中,所述混合液的质量浓度为10%~15%。
5.根据权利要求3所述的含有玫瑰发酵液的胶囊,其特征在于,步骤2)中,所述菌种选自青春双歧杆菌CICC 6175、纳豆芽孢杆菌CICC 10262、保加利亚乳杆菌CICC 20271、酿酒酵母菌CICC 1252中的至少一种。
6.根据权利要求5所述的含有玫瑰发酵液的胶囊,其特征在于,步骤2)中,所述菌种为纳豆芽孢杆菌CICC 10262、保加利亚乳杆菌CICC 20271和酿酒酵母菌CICC 1252的混合菌种,步骤3)中扩大培养后的所述纳豆芽孢杆菌CICC 10262、保加利亚乳杆菌CICC 20271和酿酒酵母菌CICC 1252种子液的质量比例为1:(2~5):(2~5)。
7.根据权利要求3所述的含有玫瑰发酵液的胶囊,其特征在于,步骤2)中,所述活化培养基为MRS培养基,包括牛肉膏5g/L,蛋白胨10g/L,葡萄糖20g/L,酵母粉4g/L,乙酸钠5g/L,硫酸镁0.2g/L,柠檬酸三铵2g/L,磷酸氢二钾2g/L,硫酸锰0.05g/L,吐温-80 1g/L,琼脂20g/L,pH值6.2±0.2。
8.根据权利要求3所述的含有玫瑰发酵液的胶囊,其特征在于,步骤2)中,所述活化培养基还包括海藻多糖,所述海藻多糖的加入量为3g/L。
9.根据权利要求3所述的含有玫瑰发酵液的胶囊,其特征在于,步骤3)中,所述摇床转速为100~150rpm。
10.根据权利要求3所述的含有玫瑰发酵液的胶囊,其特征在于,步骤1)和4)中,所述灭菌为将所述初始发酵液在121℃下灭菌15min,或对其在600MPa,25℃下进行超高压灭菌;
步骤4)中,采用高压匀浆机破碎菌体,压力设定为100MPa,匀浆3~5次,出口温度为25℃。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010836762.0A CN111920048B (zh) | 2020-08-19 | 2020-08-19 | 一种含有玫瑰发酵液的胶囊及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010836762.0A CN111920048B (zh) | 2020-08-19 | 2020-08-19 | 一种含有玫瑰发酵液的胶囊及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111920048A true CN111920048A (zh) | 2020-11-13 |
CN111920048B CN111920048B (zh) | 2022-08-16 |
Family
ID=73305339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010836762.0A Active CN111920048B (zh) | 2020-08-19 | 2020-08-19 | 一种含有玫瑰发酵液的胶囊及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111920048B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115997868A (zh) * | 2023-02-10 | 2023-04-25 | 甘肃东玫誉驰生物医药科技有限公司 | 苦水玫瑰发酵口服液及其制备方法 |
CN116270826A (zh) * | 2023-03-09 | 2023-06-23 | 中国农业科学院麻类研究所 | 一种具有提高玫瑰花降血糖和降血脂活性的方法以及应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103027231A (zh) * | 2013-01-01 | 2013-04-10 | 蒋常德 | 一种复合益生菌发酵中草药活性保健液及其制备方法 |
CN108112987A (zh) * | 2017-12-12 | 2018-06-05 | 广州农信饲料有限公司 | 一种调节胃肠道健康的功能制剂及其制备方法和应用 |
CN110200275A (zh) * | 2019-06-27 | 2019-09-06 | 湖北瑞晟生物有限责任公司 | 益生菌发酵玫瑰花渣产品及其制备 |
US20190328004A1 (en) * | 2018-04-30 | 2019-10-31 | Bruce Johnson | Metal chelates and compositions comprising metal chelates as nutritional and/or antimicrobial compositions for administration to animals |
-
2020
- 2020-08-19 CN CN202010836762.0A patent/CN111920048B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103027231A (zh) * | 2013-01-01 | 2013-04-10 | 蒋常德 | 一种复合益生菌发酵中草药活性保健液及其制备方法 |
CN108112987A (zh) * | 2017-12-12 | 2018-06-05 | 广州农信饲料有限公司 | 一种调节胃肠道健康的功能制剂及其制备方法和应用 |
US20190328004A1 (en) * | 2018-04-30 | 2019-10-31 | Bruce Johnson | Metal chelates and compositions comprising metal chelates as nutritional and/or antimicrobial compositions for administration to animals |
CN110200275A (zh) * | 2019-06-27 | 2019-09-06 | 湖北瑞晟生物有限责任公司 | 益生菌发酵玫瑰花渣产品及其制备 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115997868A (zh) * | 2023-02-10 | 2023-04-25 | 甘肃东玫誉驰生物医药科技有限公司 | 苦水玫瑰发酵口服液及其制备方法 |
CN116270826A (zh) * | 2023-03-09 | 2023-06-23 | 中国农业科学院麻类研究所 | 一种具有提高玫瑰花降血糖和降血脂活性的方法以及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN111920048B (zh) | 2022-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105054040B (zh) | 一种益生菌发酵人参的组合物及其制备方法和应用 | |
CN108991327A (zh) | 一种益生菌固体饮料及其制备方法 | |
CN108783462A (zh) | 一种肠道益生菌制剂的工业生产方法 | |
CN102318806B (zh) | 一种益生菌发酵南瓜、胡萝卜蔬菜粉的制备方法 | |
CN106754619A (zh) | 一种在谷物培养基中添加中药组分促进益生菌生长的方法 | |
CN108823129B (zh) | 一种具有抵抗幽门螺旋杆菌作用的高活性益生菌固体饮料 | |
CN111920048B (zh) | 一种含有玫瑰发酵液的胶囊及其制备方法 | |
CN113142302B (zh) | 一种具有降糖效果的益生菌酸奶及其制备方法 | |
Li et al. | In-vitro digestion by simulated gastrointestinal juices of Lactobacillus rhamnosus cultured with mulberry oligosaccharides and subsequent fermentation with human fecal inocula | |
CN111820419A (zh) | 靶向调控肠道艾克曼菌和短链脂肪酸产生菌的组合物 | |
BE1026585B1 (fr) | Procédé et application de préparation d'une matière première alimentaire médicale pour les tumeurs malignes du varech fermenté à l'aide de probiotiques | |
RU2440010C2 (ru) | Предварительно ферментированная симбиотическая матрица на основе суспензии зернового продукта, полученной с помощью иммобилизованных клеток микроорганизмов, и инкапсулированных пробиотиков - продукт и способ его получения | |
EP4012017A1 (en) | Method for preparing pure plant-based microbial culture | |
CN105559087A (zh) | 一种含燕窝酸的益生菌产品及其制备方法 | |
CN110122868B (zh) | 一种臭参酵素、臭参酵素饮品及制备方法 | |
CN111904878A (zh) | 一种含有玫瑰发酵液的脂质体的制备方法及应用 | |
CN111345473A (zh) | 一种含卵黄抗体IgY的益生菌组合物及应用制剂 | |
CN113397170B (zh) | 一种用于调节人体肠道菌群的海洋益生元组合物的应用 | |
CN109652335A (zh) | 一种饲用固态乳酸菌高活性菌剂的制备方法 | |
CN114984065A (zh) | 一种提高免疫力的益生菌组合物及其制备方法 | |
CN114606280A (zh) | 一种合生元组合物及其制备方法 | |
CN112322531A (zh) | 一种高活性嗜酸乳杆菌冻干粉的生产方法及应用 | |
CN112155199B (zh) | 一种含有灵芝子实体孢子粉发酵液的胶囊及其制备方法 | |
Elghali et al. | Variations on soymilk components during fermentation by Lactobacillus and Bifidobacterium strains | |
CN110338400A (zh) | 一种红枣酵素的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: Room 1045, building 3, No. 800, North Ring Road, Zhuangxing Town, Fengxian District, Shanghai 201402 Applicant after: Shanghai jieshibao Daily Chemical Group Co.,Ltd. Address before: Room 1045, building 3, No. 800, North Ring Road, Zhuangxing Town, Fengxian District, Shanghai, 201499 Applicant before: Shanghai Yibao cosmetics Group Co.,Ltd. |
|
CB02 | Change of applicant information | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PP01 | Preservation of patent right |
Effective date of registration: 20230418 Granted publication date: 20220816 |
|
PP01 | Preservation of patent right |